| P50 | author | Hla-Hla Thein | Q56997867 |
| P2093 | author name string | Craig C Earle | |
| | Eric M Yoshida | |
| | Ahmad Zaheen | |
| | Yao Qiao | |
| | Kelvin K W Chan | |
| | Gonzalo Sapisochin | |
| | Nathaniel Jembere | |
| P2860 | cites work | Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. | Q38207487 |
| | Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. | Q38706131 |
| | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 |
| | Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries | Q39156080 |
| | Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold | Q39268069 |
| | Health care costs associated with hepatocellular carcinoma: a population-based study | Q39489363 |
| | Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group | Q39605645 |
| | Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma | Q41004828 |
| | Physicians in health care management: 4. Case Mix Groups and Resource Intensity Weights: physicians and hospital funding | Q41036134 |
| | Physicians in health care management: 3. Case Mix Groups and Resource Intensity Weights: an overview for physicians | Q41564232 |
| | Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. | Q43000459 |
| | Cancer registration in Ontario: a computer approach | Q44626096 |
| | Health values of patients with chronic hepatitis C infection | Q45158760 |
| | Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma | Q45299134 |
| | Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection | Q45365669 |
| | The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. | Q47723189 |
| | Assessment of utilities and health-related quality of life in patients with chronic liver disease | Q48963249 |
| | Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. | Q50499409 |
| | Health-state utilities and quality of life in hepatitis C patients. | Q50583400 |
| | Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. | Q51816928 |
| | Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. | Q53388176 |
| | Costs, effects and C/E-ratios alongside a clinical trial. | Q53658625 |
| | A Caution Regarding Rules of Thumb for Variance Inflation Factors | Q56505273 |
| | Health-State Utilities and Quality of Life in Hepatitis C Patients | Q57696013 |
| | Hepatocellular carcinoma | Q57756376 |
| | Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems | Q58803348 |
| | AJCC/TNM cancer staging, present and future | Q74266807 |
| | Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada | Q82718759 |
| | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting | Q26828407 |
| | Recent advances in multidisciplinary management of hepatocellular carcinoma | Q26863748 |
| | Management of hepatocellular carcinoma: An update | Q27860530 |
| | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 |
| | Hepatocellular carcinoma | Q29615765 |
| | Hepatocellular carcinoma | Q29616359 |
| | Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation | Q31037061 |
| | Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope | Q31043509 |
| | Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions | Q31058011 |
| | Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine | Q33578537 |
| | Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis | Q33778970 |
| | Influence of socioeconomic status on survival of hepatocellular carcinoma in the Ontario population; a population-based study, 1990-2009. | Q34342497 |
| | Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases | Q34439990 |
| | Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort | Q34556277 |
| | An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma | Q34611731 |
| | Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study | Q35785156 |
| | Health state utilities and quality of life in patients with hepatitis B. | Q36091385 |
| | Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study | Q36989118 |
| | Health-state utilities in liver disease: a systematic review. | Q37142994 |
| | Economic evaluation of sorafenib in unresectable hepatocellular carcinoma | Q37805638 |
| | Multidisciplinary approach for HCC patients: hepatology for the oncologists | Q38110202 |
| | Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. | Q38122306 |
| | Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. | Q38129119 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0185198 | |
| P577 | publication date | 2017-10-10 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting | |
| P478 | volume | 12 | |